Outcomes of HIV-infected children with tuberculosis who are started on antiretroviral therapy in Malawi

International Journal of Tuberculosis and Lung Disease

Volumn 11, Issue 5, 2007, Pages 534-538

  Bong, C N ^a,b   Chen, S C C ^b   Jong, Y J ^c   Tok, T S ^b   Hsu, C F ^a   Schouten, E J ^d,e   Makombe, S D ^e   Yu, J K L ^a,b,c   Harries, Anthony D ^d,f,g  

^a Mzuzu Central Hospital   (Malawi)

^b PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d MINISTRY OF HEALTH   (Malawi)

^e Management Sciences for Health ^*  (Malawi)

^f FAMILY HEALTH INTERNATIONAL   (United States)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antiretroviral therapy; Children; Malawi; TB; Treatment outcomes

Indexed keywords

COTRIMOXAZOLE; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALAWI; MALE; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INFANT; MALAWI; MALE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 34248345517     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Harries A D, Hargreaves N J, Graham S M, et al. Childhood tuberculosis in Malawi: nationwide case-finding and treatment outcomes. Int J Tuberc Lung Dis 2002; 6: 424-431.
2. Mukadi Y D, Wiktor S Z, Coulibaly I-M, et al. Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Cote d'Ivoire. AIDS 1997; 11: 1151-1158.
3. Madhi S A, Huebner R E, Doedens L, et al. HIV-1 co-infection in children hospitalised with tuberculosis in South Africa. Int J Tuberc Lung Dis 2000; 4: 448-454.
4. Graham S M, Coulter J B S, Gilks C F. Pulmonary disease in HIV-infected African children. Int J Tuberc Lung Dis 2001; 5: 12-23.
5. World Health Organization and UNAIDS. Progress on global access to HIV antiretroviral therapy. A report on '3 by 5' and beyond. Geneva, Switzerland: WHO/UNAIDS, March 2006.
6. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach. Geneva, Switzerland: WHO, 2006.
7. World Health Organization. Antiretroviral therapy for HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for a public health approach. Geneva, Switzerland: WHO, 2006.
8. Dean G L, Edwards S G, Ives N J, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16: 75-83.
9. Hung C C, Chen M Y, Hsiao C F, et al. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS 2003; 17: 2615-2622.
10. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect 2006; 52: 188-194.
11. Libamba E, Makombe S, Harries A D, et al. Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes - the case of Malawi. Int J Tuberc Lung Dis 2005; 9: 1062-1071.
12. Malawi Ministry of Health and Population. Treatment of AIDS. Guidelines for the use of antiretroviral therapy in Malawi. 1st ed. Lilongwe, Malawi: Ministry of Health and Population, 2003.
13. Malawi Ministry of Health and Population. Manual of the National Tuberculosis Control Programme of Malawi. 5th ed. Lilongwe, Malawi: Ministry of Health and Population, 2002.
14. Kwara A, Flanigan T P, Carter E J. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis 2005; 9: 248-257.
15. Rennert W P, Kilner D, Hale M, Stevens G, et al. Tuberculosis in children dying with HIV-related lung disease: clinical-pathological correlations. Int J Tuberc Lung Dis 2002; 6: 806-813.
16. Barlow-Mosha L, Musoke P, Ajuna P, et al. Early effectiveness of Triomune in HIV-infected Ugandan children. Abstract WeOa0103. Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil: 2005.
17. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire. AIDS 2004; 18: 1905-1913.
18. Eshelman S H, Jackson J B. Nevirapine resistance after single dose prophylaxis. AIDS 2002; 4: 59-63.
19. Flys T, Nissley D V, Claasen C W, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192: 24-29.
20. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Eng J Med 2005; 351: 229-240.
21. The Antiretroviral Therapy in Lower-Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817-824.
22. Lawn S D, Myer L, Orrell C, Bekker L-G, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19: 2141-2148.
23. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006; 20: 2355-2360.
24. Corbett E L, Marston B, Churchyard G J, De Cock K M. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367: 926-937.